Fact CheckerSign in

NCT07287345RecruitingPhase 4

Colchicine's Effect on Inflammatory Markers

Adjunctive Colchicine's Effect on Inflammatory Markers and Corresponding New-Onset Atrial Fibrillation Rates Post Coronary Artery Bypass Graft Procedure: A Pilot Study

Source: ClinicalTrials.gov · Last updated 25 Jun 2026

Brief summary (registry, in English)

This study wants to see if the medicine colchicine can help lower inflammation and reduce the chance of developing an irregular heartbeat (atrial fibrillation) after heart bypass surgery. Adults having coronary artery bypass surgery (CABG) can join. Participants will be randomly placed into one of two groups: one group will receive colchicine along with usual care, and the other will receive a placebo (a look-alike capsule with no medicine) along with usual care. Everyone will take a study capsule, and neither the patients nor the study team will know which capsule is being given. Everyone in the study will take study capsule, and neither the patients nor the study team will know who is receiving colchicine or placebo. Blood samples and health information will be collected before surgery; at 24, 48, 72, and 96 hours after surgery; and again at 10 days after surgery or at hospital discharge, whichever comes first. The investigators will look at inflammation marker levels, whether atrial fibrillation happens, and any side effects. This small study will help to generate effect size estimates and safety data that will help plan a larger study in the future.

Status (registry)
Recruiting
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
24 (estimated)
First submitted
1 Dec 2025
Start date
16 Jan 2026
Primary completion date
30 Dec 2026
Lead sponsor
Ayesha Ather
NCT number
NCT07287345

What you commit to

  • Study type: Interventional · Phase 4
  • Planned participants: 24
  • From 16 Jan 2026 to the primary completion date, 30 Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Current treatment with colchicine for any cause

Other illness

  • History of atrial fibrillation
  • Hypersensitivity to colchicine (as indicated by rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever)
  • Emergency cardiac surgery
  • Extracorporeal Membrane Oxygenation (ECMO) pre- or post-cardiac surgery
  • Heart transplant patients
  • Chronic intestinal disease or blood dyscrasia

Lab values

  • Serum creatinine \>2.0 mg/dL
  • Severe liver disease or elevation of serum transaminases (\>1.5 times the upper limit of 40 units/liter)

Other

  • Off-pump CABG procedure
  • Left ventricular assist device (LVAD) patients
  • Preoperative elevated CK or known myopathy
  • Unable to speak English
  • Pregnancy or lactation in women

Who the study is looking for

  • Age 18 years and older
  • Coronary artery bypass graft (CABG) planned procedure

Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Kentucy
Coordinator of this site? Confirm its status
LexingtonUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.